Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options
Top Cited Papers
Open Access
- 2 February 2015
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 36 (01), 085-098
- https://doi.org/10.1055/s-0034-1398388
Abstract
The first decade of the 20th century witnessed a surge in the incidence of infections due to several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter baumannii is one such organism that turned from an occasional respiratory pathogen into a major nosocomial pathogen. An increasing number of A. baumannii genome sequences have broadened our understanding of the genetic makeup of these bacteria and highlighted the extent of horizontal transfer of DNA. Animal models of disease combined with bacterial mutagenesis have provided some valuable insights into mechanisms of A. baumannii pathogenesis. Bacterial factors known to be important for disease include outer membrane porins, surface structures including capsule and lipopolysaccharide, enzymes such as phospholipase D, iron acquisition systems, and regulatory proteins. A. baumannii has a propensity to accumulate resistance to various groups of antimicrobial agents. In particular, carbapenem resistance has become commonplace, accounting for the majority of A. baumannii strains in many hospitals today. Carbapenem-resistant strains are often resistant to all other routinely tested agents. Treatment of carbapenem-resistant A. baumannii infection therefore involves the use of combinations of last resort agents such as colistin and tigecycline, but the efficacy and safety of these approaches are yet to be defined. Antimicrobial-resistant A. baumannii has high potential to spread among ill patients in intensive care units. Early recognition and timely implementation of appropriate infection control measures is crucial in preventing outbreaks.Keywords
This publication has 158 references indexed in Scilit:
- Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control studyClinical Microbiology & Infection, 2012
- Environmental contamination because of multidrug-resistant Acinetobacter baumannii surrounding colonized or infected patientsAmerican Journal of Infection Control, 2011
- The pmrCAB Operon Mediates Polymyxin Resistance in Acinetobacter baumannii ATCC 17978 and Clinical Isolates through Phosphoethanolamine Modification of Lipid AAntimicrobial Agents and Chemotherapy, 2011
- Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory SystemAntimicrobial Agents and Chemotherapy, 2011
- Overexpression of Resistance-Nodulation-Cell Division Pump AdeFGH Confers Multidrug Resistance in Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2010
- Frequent Multidrug-ResistantAcinetobacter baumanniiContamination of Gloves, Gowns, and Hands of Healthcare WorkersInfection Control & Hospital Epidemiology, 2010
- Epidemiology and Impact of Imipenem Resistance in Acinetobacter baumanniiInfection Control & Hospital Epidemiology, 2009
- Overexpression of the Naturally Occurring bla OXA-51 Gene in Acinetobacter baumannii Mediated by Novel Insertion Sequence IS Aba9Antimicrobial Agents and Chemotherapy, 2009
- New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesisGenes & Development, 2007
- Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2006